Vericell Corporation reported third-quarter 2026 revenue of $85.4 million, up 26%, and raised full-year revenue guidance to $344 million to $346 million. Adjusted EBITDA rose 48% to $25.2 million, with adjusted EBITDA margin at 30%.
VCEL · Vericel Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Vericel Corporation reported 231,253 in revenue and 10,065 in net income, in thousands, for the nine months ended September 30, 2026, with revenue up 26.1%. In July 2026, the board authorized up to $200.0 million of share repurchases with no expiration date.
Vericel Corporation reported third-quarter revenue growth of 26% to $85.4 million and net income growth of 179% to $14.2 million, raising full-year revenue guidance to $344 to $346 million and adjusted EBITDA margin guidance to 28%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Vericel posted Q2 revenue of $77.5M (up 22%) driven by MACI (+23%) and Burn Care (+22%), delivered $2.2M GAAP net income and $14.3M of free cash flow, raised full-year 2026 revenue guidance to $330–$340M and authorized a $200M share repurchase program.
- + Q2 total revenue grew 22% to $77.5M, above guidance, driven by MACI up 23% and Burn Care up 22%.
- + Company raised full-year 2026 total revenue guidance to $330–$340M and raised MACI and Burn Care guidance.
- + First-half 2026 results were strong with 26% total revenue growth, 47% adjusted EBITDA growth and nearly $30M of free cash flow.
- + NexoBrid posted record quarterly revenue of $1.5M+, up 30%+ year-over-year and quarter-over-quarter, with record ordering centers and hospital units.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| MACI net revenue | $67.37M | FY2026 Q3 | +21.0% |
|
|
|||
| Burn Care net revenue | $12M | second quarter ended June 30, 2026 | — |
| Epicel revenue growth | 21% | second quarter ended June 30, 2026 | — |
| Free cash flow non-GAAP | $29.4M | Six Months Ended June 30, 2026 | — |
| Gross margin | 73% | second quarter ended June 30, 2026 | — |
| NexoBrid revenue growth versus prior quarter | 36% | second quarter ended June 30, 2026 | — |
| NexoBrid revenue growth versus prior year | 33% | second quarter ended June 30, 2026 | — |
| Non-GAAP adjusted EBITDA margin non-GAAP | 19% | second quarter ended June 30, 2026 | — |
| Operating cash flow | $32.6M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VCEL
this stock
Vericel Corp
|
$2.91B | +58.2% | +16.5% | 87.6 | 10.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 16
Vericel Corporation reported 231,253 in revenue and 10,065 in net income, in thousands, for the nine months ended September 30, 2026, with revenue up 26.1%. In July 2026, the board authorized up to $200.0 million of share repurchases with no expiration date.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VCEL | +4.3% | +41.9% | +62.9% | +41.5% | +58.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +1.7% | +43.1% | +62.4% | +41.7% | +47.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.